Adjunctive Pathways to Optimize Dopamine Levels in Parkinson's Disease

This section discusses emerging and adjunctive therapies designed to address motor fluctuations in patients with Parkinson’s disease beyond traditional levodopa therapy. The speaker highlights dopamine agonists as established options that enhance dopaminergic activity and introduces newer approaches such as the subcutaneous apomorphine pump, which can increase “on” time while reducing dyskinesia and “off” periods. Catechol-O-methyltransferase inhibitors are also discussed, which prolongs levodopa’s effect by preventing its peripheral breakdown and improving delivery to the brain. The conversation emphasizes that these therapies can enhance the effectiveness of levodopa and improve symptom control. Finally, the speaker underscores the importance of incorporating on-demand therapies into treatment strategies, suggesting a shift in how clinicians approach adjunctive management of motor fluctuations.